- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Leading Healthcare-Focused Venture Funds Announce Investment of up to $430 Million in Saama
Saama Technologies (Campbell, CA) has announced that venture funds led by global investment firm Carlyle have made a strategic growth investment in the company. Investing alongside Carlyle is a broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners.
The partnership will allow Saama to accelerate its strategic initiatives, including expanding its go-to-market capabilities and further investing in AI research and development.
Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies. It provides a unified approach to clinical trial data management and analytics and its AI-embedded smart applications have the ability to learn the complex patterns among clinical data and provide predictive insights to accelerate the clinical research process across a variety of domains and therapeutic areas.
“The life sciences industry is experiencing a massive shift in strategic approaches to accelerating drug development as a result of the COVID-19 pandemic, and AI-driven analytics solutions like Saama’s LSAC are at the forefront. These solutions’ role in successfully enabling the delivery of COVID-19 vaccines and therapies to patients in mere months was the litmus test for the future of drug development,” said Suresh Katta, Founder and CEO, Saama Technologies.
David M. Rubin, Ph.D., Managing Director at Merck Global Health Innovation Fund, commented: “Merck GHI sees tremendous opportunity in Saama’s mission of accelerating clinical trials. It is very exciting to be part of a world-class investment syndicate with such deep healthcare domain expertise and interest in supporting the build of scaled resources that have the potential to change the way clinical research and development is conducted.”
The investment in Saama is a continuation of Carlyle’s global commitment to healthcare and technology, in which it has invested $17 billion and $25 billion of equity since inception, respectively – including $2 billion in healthcare technology and tech-enabled growth companies.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
